证券代码：688029 证券简称：南微医学 公告编号：2025-051 会议召开时间：2025年12月16日（星期二）上午10:00-11:00 会议召开方式：上证路演中心网络互动 会议召开平台：上海证券交易所上证路演中心 （一） 会议召开时间：2025年12月16日（星期二）上午10:00-11:00 （二） 会议召开方式：上证路演中心网络互动 （三） 会议召开平台：上海证券交易所上证路演中心 （网址：http://roadshow.sseinfo.com/） 南微医学科技股份有限公司 关于召开2025年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 投资者可于2025年12月9日(星期二)至12月15日(星期一)16:00前登录上 证路演中心网站首页点击"提问预征集"栏目或将有关问题通过电子邮件 的形式发送至公司投资者关系邮箱nwyx@mtmed.com。公司将在说明会上对 投资者普遍关注的问题进行回答。 一、 ...

证券代码：688029 证券简称：南微医学 公告编号：2025-050 南微医学科技股份有限公司 关于收到《无效宣告请求审查决定书》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 专利权人：南微医学科技股份有限公司 公司于2025年12月5日收到中华人民共和国国家知识产权局（以下简称"国家 知识产权局"）出具的《无效宣告请求审查决定书》（第601086号）。国家知识产 权局对北京中科盛康科技有限公司（以下简称"中科盛康"）提出的有关公司所持 有的"一种止血夹"发明专利无效宣告请求进行了审查。现将有关情况公告如下： 一、本次事项的基本情况 2025年5月16日，无效宣告请求人中科盛康以公司"一种止血夹"（专利号： 201410222753.7）发明专利的权利要求不具有创造性等理由，向国家知识产权局提 出无效宣告请求。具体内容详见公司于2025年5月30日在上海证券交易所网站 （www.sse.com.cn）披露的《南微医学科技股份有限公司关于收到<无效宣告请求 1 无效宣告请求审查结果：中华人民共和国 ...

证券代码：688029 证券简称：南微医学 公告编号：2025-049 一、减持主体减持前基本情况 南微医学科技股份有限公司 持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，深圳市中科招商创业投资有限公司（以下简称"中科 招商"）持有南微医学科技股份有限公司（以下简称"公司"）股份 41,752,818 股，占公司总股本的 22.2270%。上述股份来源为公司首次公开发行股票并上市 前取得的股份，及该等股份于公司 2022 年实施资本公积转增股本时获得股份， 上述股份已于 2022 年 7 月 22 日起上市流通。 减持计划的实施结果情况 2025 年 8 月 18 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《南微医学科技股份有限公司持股 5%以上股东减持股份计划公告》（公告编号： 2025-036），公司股东中科招商拟通过上海证券交易所交易系统以集中竞价、大 宗交易方式减持公司股份合计不超过 ...

南财智讯12月5日电，南微医学公告，公司股东深圳市中科招商创业投资有限公司（简称"中科招商"） 在2025年9月30日至2025年10月9日期间，通过集中竞价交易方式合计减持公司股份62,000股，占公司总 股本的0.03%，减持价格区间为97.50至100.90元/股，累计减持金额622.49万元。本次减持后，中科招商 持股比例由22.2270%下降至22.1940%。截至2025年12月5日，本次减持计划期限届满，实际减持数量未 完成原计划的3,756,948股，剩余3,694,948股未实施减持。本次减持行为符合相关法律法规及此前披露的 减持计划。 ...

Core Insights - As of December 2, a total of 128 stocks in the Shanghai and Shenzhen markets have experienced net buying through financing for five consecutive days or more [1] - The stock with the longest consecutive net buying days is Zhongchen Technology, which has seen net buying for 12 trading days [1] - Other notable stocks with significant consecutive net buying days include Saiwei Electronics, Hunan Gold, Huaxi Securities, Huada Technology, Shanghai Airport, Zhejiang Xinneng, Xiangyang Bearing, and Nanwei Medical [1]

Group 1 - The 2025 Analyst Conference and the 7th Sina Finance "Golden Unicorn" Best Analyst Awards Ceremony were held in Shanghai, gathering over 300 industry experts to discuss future opportunities in the Chinese capital market [1] - The top honor for the 7th Sina Finance Golden Unicorn Elite Analyst in the innovative drug sector was awarded to the Zheshang Securities research team, led by Chief Analyst Wu Tianhao [1] Group 2 - The strategy for the high-value consumables sector in 2026 indicates optimism due to policy optimization, with expectations for revenue recovery and new product launches [2] - The medical device sector is expected to see performance recovery driven by the resumption of in-hospital bidding and the "Belt and Road" initiative, despite a decline in profit in the first three quarters of 2025 [2] - The home medical sector is anticipated to regain growth, supported by overseas expansion and recovery in revenue and profit growth in 2025 [2] Group 3 - Investment recommendations include high-value consumables companies with cleared procurement risks and new product launches, such as Microelectrophysiology, Aikang Medical, and Weikang Medical [3] - Medical device and home medical companies expected to see steady revenue growth include Mindray Medical, Meihua Medical, and Yuyue Medical, among others [3]

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [5]. Core Insights - The report emphasizes the importance of seizing opportunities following market corrections, particularly in anticipation of improvements in 2026. It notes that the pharmaceutical sector's fundamentals remain strong despite recent market fluctuations, and it is currently at a valuation bottom. The report suggests focusing on innovative drugs and companies with potential for operational improvements in 2025 [7][11]. Summary by Sections Industry Overview - The pharmaceutical sector consists of 498 listed companies with a total market capitalization of approximately 70,594.11 billion [2]. - The sector has experienced a decline of 6.88% recently, with various sub-sectors such as pharmaceutical commerce and biopharmaceuticals also facing downturns [11]. Market Dynamics - The report highlights a significant market correction, with the Shanghai Composite Index down by 3.77% and the pharmaceutical sector underperforming [11]. - It notes that the overall performance of the pharmaceutical sector has been positive since the beginning of the year, with a return of 13.69%, slightly outperforming the broader market [18]. Investment Opportunities - The report identifies key companies to watch, including: - CDMO leaders: WuXi AppTec, WuXi Biologics, and WuXi AppTec [11]. - Front-end CROs: Tigermed, ProPhase, and Zhaoyan New Drug [11]. - Medical devices: United Imaging Healthcare and HaiTai New Light [11]. - Biopharmaceuticals: I-Mab Biopharma and Hualan Biological Engineering [11]. - It also suggests focusing on companies with innovative drug pipelines and those that are transitioning from biotech to biopharma [11]. Company Performance - The report provides a list of recommended stocks, including: - WuXi AppTec (66.45), rated "Buy" - Three Life Pharmaceuticals (29.34), rated "Buy" - Tigermed (49.59), rated "Buy" - Xiansheng Pharmaceutical (12.85), rated "Buy" - Betta Pharmaceuticals (48.60), rated "Buy" [5][31]. Regulatory and Market Trends - The report discusses recent regulatory developments, including a call from the vaccine industry association to avoid low-cost bidding practices to stabilize profit margins for leading vaccine companies [11][12]. - It also notes significant acquisitions and advancements in drug development, such as Johnson & Johnson's acquisition of Halda Therapeutics for $30.5 billion [11].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][48]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a 3.29% increase in the biopharmaceutical sector, while the total A-share market declined by 0.09% [1][36]. - The report highlights a significant divergence in performance among different segments of the medical device market, with consumables growing faster than equipment and IVD products [2][19]. - The report emphasizes the long-term growth potential of the Chinese medical device market despite short-term challenges related to pricing and policy [2][20]. Summary by Sections Market Performance - The biopharmaceutical sector outperformed the overall market, with notable increases in various sub-sectors: chemical pharmaceuticals up 4.51%, bioproducts up 2.65%, medical services up 1.81%, medical devices up 1.77%, and traditional Chinese medicine up 4.08% [1][36]. Key Companies and Predictions - Major companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion CNY [4][48]. - Mindray Medical is highlighted for its strong R&D and sales capabilities, benefiting from domestic medical infrastructure and international expansion [48]. - WuXi AppTec is recognized for its comprehensive drug development services, poised to benefit from the rapid growth of the global drug development outsourcing market [48]. Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already reflected risks from policies like centralized procurement [46][47]. - It recommends monitoring the clinical progress of innovative drugs overseas and emphasizes the importance of global clinical data for commercialization [47][48]. Recommended Stocks - The report lists several recommended stocks, including Mindray Medical, WuXi AppTec, Aier Eye Hospital, and others, indicating their strong market positions and growth potential [48][49].

Core Viewpoint - Nanwei Medical's stock price has experienced fluctuations, with a recent decline of 2.08% and a year-to-date increase of 24.22% [1][2]. Group 1: Stock Performance - As of November 17, Nanwei Medical's stock price is 82.11 CNY per share, with a market capitalization of 15.424 billion CNY [1]. - The stock has seen a decline of 1.00% over the last five trading days, 5.62% over the last 20 days, and 15.71% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Nanwei Medical reported a revenue of 2.381 billion CNY, representing a year-on-year growth of 18.29%, and a net profit attributable to shareholders of 509 million CNY, up 12.90% year-on-year [2]. - The company has distributed a total of 978 million CNY in dividends since its A-share listing, with 664 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Nanwei Medical is 12,500, an increase of 1.38% from the previous period [2]. - The average number of circulating shares per shareholder is 15,009, which has decreased by 1.36% from the previous period [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fifth largest with 3.6594 million shares, while Huabao CSI Medical ETF has reduced its holdings by 459,000 shares [3].

证券代码：688029 证券简称：南微医学 公告编号：2025-048 南微医学科技股份有限公司 2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 网络投票相结合的方式进行表决。本次会议的召集和召开程序以及表决方式和表 决程序均符合《公司法》及《公司章程》的规定，会议合法有效。 （五） 公司董事、监事和董事会秘书的出席情况 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 12 日 （二） 股东大会召开的地点：南京江北新区药谷大道 199 号公司 9 楼会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 118 | | --- | --- | | 普通股股东人数 | 118 | | 2、出席会议的股东所持有的表决权数量 | 97,933,827 | | 普通股股东所持有表决权数量 | 97,933,827 | | 3、出席会 ...